US Bancorp’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

US Bancorp’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-21	Closed	-$3K	–	4032
2020 Q4	$3K	Hold	21	–	–	﹤0.01%	3545
2020 Q3	$1K	Buy	+21	New	+$944	﹤0.01%	3674

US Bancorp's EIDX Position: Q1 2021 in Review

US Bancorp sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 21 shares — an estimated $3K sold.

US Bancorp first reported a position in EIDX in Q3 2020 and held it in 2 quarters. The position peaked at $3K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

US Bancorp reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
US Bancorp sold 21 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $3K.
US Bancorp first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
US Bancorp's Eidos Therapeutics, Inc. Common Stock position peaked at $3K in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on US Bancorp's 13F filing for Q1 2021, filed 28 Apr 2021.